Top India Companies To Buy For 2014

Gold is one of the most influential financial instruments in the India. Banks, NBFCs and unorganized lenders are actively engaged in providing loans against gold value. The loan against value of gold has played a great role by providing liquidity for an idle asset kept in the lockers. However, in its latest move, RBI has come up with a norm for NBFCs that does not allow them to offer a loan above 60% of the value of gold.

RBI grew uncomfortable with the high growth rate of gold loans for NBFCs. It has increased its inquiry of the gold loan portfolios, even for the banks. RBI wants interest rates and growth rates on gold loans to come down, especially for NBFCs considering concentration risk and the risk of a fall in gold prices.

Furthermore, RBI�� directive that a bank credit to NBFCs for giving loans against gold jewelry will not be treated as exposure to the agricultural sector would hinder companies to raise easy funds for gold financing.
Some of the key points from the RBI�� latest guidelines for NBFCs include transparency in interest rates, due diligence in understanding the repayment capacity of the borrower, awareness of his existing debts, explicit loan agreement etc. Also, NBFCs that have gold loans of more than 50% of total financial assets have to maintain Tier -1 capital ratio of 12% from April 2014.

Top Semiconductor Companies To Watch For 2015: Dr. Reddy's Laboratories Ltd(RDY)

Dr. Reddy?s Laboratories Limited, together with its subsidiaries, operates as a pharmaceutical company. It produces finished dosage forms, active pharmaceutical ingredients and intermediates, and biotechnology products. The company also conducts research in the areas of cancer, diabetes, cardiovascular, inflammation, and bacterial infection. In addition, it involves in the contract manufacture generic prescription and over-the-counter products for branded and generic companies in the United States. The company primarily focuses on therapeutic categories of cardiovascular, diabetes management, gastro-intestinal, and pain management. It markets its products in India, the United States, Europe, and the Russian Federation. The company has a co-development and commercialization agreement with Rheoscience A/S for the development and commercialization of Balaglitazone/DRF 2593, a partial PPAR-gamma agonist for the treatment of type 2 diabetes; an agreement with ClinTec Internatio nal for the development of an anti-cancer compound, DRF 1042; collaboration with the National Cancer Institute in Maryland; and an agreement with Argenta Discovery Limited for the joint development and commercialization of a novel approach to the treatment of chronic obstructive pulmonary disease. It also has an agreement with 7TM Pharma for drug discovery collaboration on selected drug targets; and an agreement with GlaxoSmithKline plc to develop and market pharmaceuticals for the treatment of cardiovascular disease, diabetes, oncology, gastroenterology, and pain management. Dr. Reddy?s Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.

Advisors' Opinion:

• [By Monica Gerson]

  Dr. Reddy's Laboratories (NYSE: RDY) is expected to report its Q4 earnings at $0.52 per share.

  YuMe (NYSE: YUME) is estimated to post a Q1 loss at $0.15 per share on revenue of $35.36 million.

• [By Ben Levisohn]

  Teva has dropped 7.7% to $37.85 today at 3:23 p.m. but doesn’t seem to be spreading though the generic drug space. Taro Pharmaceuticals (TARO) ha gained 1.1% to $79, while Actavis (ACT) has gained 1.2% to $156.25 and Dr. Reddy’s Laboratories (RDY) has advanced 1% to $40.24. Mylan (MYL) has dropped 0.7% to $38.40.

• [By Seth Jayson]

  Dr. Reddy's Laboratories (NYSE: RDY  ) reported earnings on May 14. Here are the numbers you need to know.

  The 10-second takeaway
  For the quarter ended March 31 (Q4), Dr. Reddy's Laboratories beat expectations on revenues and beat expectations on earnings per share.

• [By Benjamin Shepherd] We’re now into day 15 of the US government shutdown, as House Republicans stubbornly try to defund Obamacare. No matter what sort of deal is eventually struck, health care costs aren’t likely to come down any time soon. And that’s good news for generic drug makers.
  
  Dr. Reddy’s Laboratories (NYSE: RDY) is one of the biggest players in generic drugs, offering more than 200 off-brand medications in the areas of cardiovascular disease, pain management and oncology, among others. In fact, this India-based company has become one of the largest makers of generics in the world, helping to drive more than 20 percent annual compounded earnings growth at the company over the past decade.

Top India Companies To Buy For 2014: Tata Motors Ltd(TTM)

Tata Motors Limited, an automobile company, engages in the manufacture and sale of commercial and passenger vehicles primarily in India. The company offers cars, utility vehicles, trucks, buses and coaches, and defense vehicles, as well as develops electric and hybrid vehicles for personal and public transportation. It also involves in distributing and marketing cars; and financing the vehicles sold by the company. In addition, the company engages in the provision of engineering and automotive solutions, as well as machine tools and factory automation solutions; construction equipment manufacturing; automotive vehicle components manufacturing and supply chain activities; tooling and plastic and electronic components for automotive and computer applications; and automotive retailing and service operations. It offers its products and services through its dealership, sales, services, and spare parts network. The company also markets its commercial and passenger vehicles in Eu rope, Africa, the Middle East, South East Asia, South Asia, and South America. The company was formerly known as Tata Engineering and Locomotive Company Limited and changed its name to Tata Motors Limited in July 2003. Tata Motors Limited was founded in 1945 and is based in Mumbai, India.

Advisors' Opinion:

• [By Justin Loiseau]

  March sales data from�Tata Motors� (NYSE: TTM  ) �show business is booming for its Jaguar Land Rover subsidiary.

  Overall sales clocked in at 53,772 units, up 16.4%�from March 2012, and longer-term trends tell a similar story. In the past 12 months, sales have headed even higher, up 22.5% to 374,669. Jaguar sales are up 8.1% in the last year, while Land Rover carried the carline with a 25.6% boost.

• [By James Well]

  Pfizer�� Net Income Growth Is Increasing Leading to Increase in Its Operating Margins
  
  Net incomes and operating margins of a company give some insights into its financial health. Pfizer�� net income growth has accelerated this year. In fact, when compared with its direct competitors like Merck, Novartis, and Sanofi, the rate of increase of net income growth trailing twelve months (TTM) is greatest at Pfizer with $10.68 billion followed by Novartis with $9.37 billion while Merck and Sanofi lagged behind with $4.53 billion and $4.05 billion respectively. Really, rather than increasing, there has been a decrease in Merck�� and Sanofi�� net incomes this year which should be a source of concern for investors. A healthy operating margin shows that a company is earning more per dollar of sales and, hence, able to pay for its fixed costs including interest on debt.

• [By Justin Loiseau]

  Tata Motors (NYSE: TTM  ) released April sales numbers for its luxury Jaguar and Land Rover vehicle lines today, and sales are soaring.

• [By Justin Loiseau]

  India and Australia just edged a little closer in the corporate car world. India's Tata Motors (NYSE: TTM  ) announced today that it will enter the Australian market under a new third-party distributor, M/s Fusion Automotive Pty Ltd. Australia.

Top India Companies To Buy For 2014: Stewart Information Services Corporation(STC)

Stewart Information Services Corporation provides title insurance and related information services required for settlement by the real estate and mortgage industries. It operates in two segments, Title Insurance-Related Services and Real Estate Information. The Title Insurance-Related Services segment offers services that include searching for and examining documents, such as deeds, mortgages, wills, divorce decrees, court judgments, liens, paving assessments, and tax records, as well as provides titles insurance for residential and commercial properties, undeveloped acreage, farms, ranches, and water rights. This segment serves attorneys, builders, developers, home buyers and home sellers, lenders, and real estate brokers. The Real Estate Information segment offers products and services, which primarily include lender services, title technology, foreign and domestic government services, mapping, title information, Internal Revenue Code Section 1031 tax-deferred property e xchanges, pre-employment services, and online filing and transaction management. Its customers include mortgage lenders and servicers, mortgage brokers, mortgage investors, government entities, commercial and residential real estate agents, land developers, builders, title insurance agencies, and others interested in obtaining property information, as well as accountants, attorneys, investors, and employers. The company has operations primarily in the United States, Canada, the United Kingdom, central Europe, Mexico, central America, and Australia. Stewart Information Services Corporation was founded in 1893 and is based in Houston, Texas.

Advisors' Opinion:

• [By Ben Levisohn]

  Tower Group has dropped 12% to $3.88 today at 11:39 a.m., while Stewart Information Services (STC) has dipped 0.1% to $31.16, the�Navigators Group�(NAVG) has fallen 1.4% to $54.78 and HCI Group�(HCI) has gained 1% to $38.16.

Top India Companies To Buy For 2014: Infosys Technologies Limited(INFY)

Infosys Ltd. provides information technology (IT) and consulting services worldwide. It offers IT services, such as application, architecture, independent validation and testing, information management, infrastructure, packaged application, SOA, systems integration, and knowledge services; product engineering services, manufacturing process and plant solutions, and product lifecycle management services; and consulting services in the areas of information and technology strategies, product innovation, next generation commerce, process excellence, and learning and complex change. The company also provides business process outsourcing solutions in the areas of business platforms, customer service outsourcing, finance and accounting, human resources outsourcing, legal services, sales and fulfillment, and sourcing and procurement outsourcing. In addition, it offers collaborative analytics solutions; digital consumer platform; Finacle universal banking solution; iProwe, a Web ac cessibility assessment product; mConnect, a real-time enterprise middleware; and research and analytical support services. Further, the company offers unified communications and collaboration solution that streamlines business processes between employees, customers, and suppliers; iTransform that helps healthcare organizations accelerate transition to new platforms; and supply chain visibility and collaboration product suite. It serves aerospace and defense, airlines, automotive, banking, capital markets, communication services, consumer packaged goods, manufacturing, education, energy, healthcare, high technology, hospitality and leisure, insurance, life sciences, logistics and distribution, publishing, resources, utilities, and retail industries. Infosys Ltd. has a strategic partnership with Alstom SA. The company was formerly known as Infosys Technologies Limited and changed its name to Infosys Ltd. on June 16, 2011. Infosys Ltd. was founded in 1981 and is headquartered i n Bengaluru, India.

Advisors' Opinion:

• [By Monica Gerson]

  Infosys (NASDAQ: INFY) is expected to report its Q2 earnings at $0.70 per share on revenue of $2.01 billion.

  Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets

• [By Michael Flannelly]

  Shares of Infosys Ltd (INFY) spiked in pre-market trading on Friday after the software company posted second quarter earnings and revenues that beat Wall Street expectations.

  The India-based company posted a second quarter net income of $383 million, or 67 cents per share, down from $431 million, or 75 cents per share, posted in the same period last year.

  The company’s earnings per American Depository Share, or ADR, came in at 73 cents per share. According to analysts at Thomson Reuters, the company was expected to earn 70 cents per share in the quarter.

  Infosys’ quarterly revenues came in at $2.066 billion, up from the $1.797 billion posted in the same quarter last year. On average, analysts were expecting the company to see $2.01 billion in revenues.

  “During the quarter we witnessed broad-based volume growth, robust client additions, five large deal wins and increased sales momentum of our big data and cloud offerings. This growth is a result of our focus on execution, which helps our clients achieve their objectives.” said S. D. Shibulal, CEO and Managing Director.

  “We will continue with planned investments and initiatives to explore new avenues of growth. We remain watchful of the sustainability of improving global economic fundamentals”, he added.

  Looking ahead, the company sees revenues growing between 9% and 10% in fiscal 2014.

  Infosys shares were up $2.72, or 5.41%, during pre-market trading on Friday. The stock is up 18.87% year-to-date.

• [By Dan Caplinger]

  Overall, the most popular emerging market ETFs experienced much sharper declines than the less-than-1% drop the Dow posted this week. Vanguard Emerging Markets (NYSEMKT: VWO  ) and iShares Emerging Markets (NYSEMKT: EEM  ) were both down just under 3% for the week. But when you drill down to look for particular culprits in the emerging markets, you don't have to look very far to find that it was generally a broad-based decline:

  In China, more concerns about a slowdown in the manufacturing industry put pressure on stocks. The Shanghai index didn't move much, but one key ETF tracking the Chinese market sank nearly 4% in response to the news, largely on weakness in telecom giant China Mobile (NYSE: CHL  ) , which plays a commanding role in many emerging market-focused ETFs.
  � Indian stocks suffered from some of the same macroeconomic issues, with the Bombay market's index down about 3% and ETF tracking the market falling 4% to 5%. The Indian finance minister responded to the decline, which many blamed on Fed Chair Ben Bernanke's comments, by saying, "We think that Bernanke's statement has been misunderstood or misinterpreted." Yet that didn't seem to appease investors in outward-directed industries like Infosys (NYSE: INFY  ) , whose IT offerings require health activity levels not just in India but in the U.S. and other customer-heavy countries as well.
  � Stocks in Mexico suffered declines of almost 5%, retracing some ground after an extraordinarily strong stretch of gains on optimism about the country's ability to reinvigorate its economy beyond its core reliance on petroleum and to resolve ongoing conflicts with drug cartels.

  But there were some relatively bright spots in other emerging markets. Brazilian stocks were actually up a bit on the week, as the nation found itself better insulated from all the happenings in Asia related to China and Japan. Russian stocks also remained relatively stable,